GlassScriptPhysician profile
Melanie B Thomas
NPI 1225134075
$26,975.50
in general payments reported to CMS, 2019-2025
40 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $8,267 · 2021: $434 · 2022: $498 · 2023: $787 · 2024: $425 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.99 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $22,134.65 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $2,671.86 | 2019-2023 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $332.12 | 2019-2024 | Imbruvica, Carvykti, Darzalex |
| Celgene Corporation | $284.91 | 2021-2024 | Pomalyst, Reblozyl |
| Daiichi Sankyo INC. | $141.97 | 2022-2024 | Injectafer, Vanflyta, Enhertu |
| Aveo Pharmaceuticals, INC. | $117.69 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $107.26 | 2020-2024 | Tagrisso |
| Novartis Pharmaceuticals Corporation | $105.95 | 2022-2023 | |
| Tempus Ai, INC | $87.47 | 2025 | Xt Cdx |
| Genzyme Corporation | $83.52 | 2019-2023 | |
| Glaxosmithkline, LLC. | $72.93 | 2021-2023 | Shingrix |
| Genmab U.S., INC. | $67.63 | 2023-2024 | Tivdak |
| Amgen INC. | $65.95 | 2021-2023 | Lumakras |
| Exelixis INC. | $62.71 | 2021-2024 | Cabometyx |
| Pfizer INC. | $62.09 | 2021-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.